


Intec Pharma appoints R. Michael Gendreau as Chief Medical Officer

05 February 2018 | News

Industry Veteran brings over 30 years of experience in drug development



Israel based Intec Pharma Ltd. is a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill™ platform technology.

The company has announced that it has named R. Michael Gendreau, M.D., Ph.D. to the position of Chief Medical Officer.

Dr. Gendreau, a seasoned industry veteran, brings to Intec Pharma over 30 years of experience in the drug development and pharmaceutical industry.

Dr. Gendreau joins Intec after having founded a consulting firm providing strategic advice on the design and management of clinical programs, strategic planning, and technology assessments for emerging pharmaceutical, diagnostic, and medical device companies.

He has served on various scientific advisory boards, executive strategic planning boards, and Data Safety Monitoring Boards.

Prior to his consulting career, Dr. Gendreau served as Chief Medical Officer at Cypress Bioscience, Inc., a clinical-stage biotech company developing therapies for central nervous system disorders.

Additionally, he has served as Chief Medical Officer at other institutions including Battelle Memorial Institute. Dr. Gendreau received his B.S. in Chemistry from Ohio University, and earned his M.D. /Ph.D. from The Ohio State University.